Patients needing intubation and mechanical ventilation for COVID-19 related pneumonia without other primary causes of ICU admission

COVID-19

Mechanical Ventilation

Quality of Life

Radiologic Increased Density of Lung

Sedation

Complication of Treatment

Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia

Invasive mechanical ventilation

Ospedale Santa Maria Annunziata - Anestesia e Rianimazione

A.O. SS. Antonio, Biagio e Cesare Arrigo - Anestesia e Rianimazione

Anestesia e Rianimazione - Ospedale Civile di Baggiovara

Anestesia e Rianimazione - Ospedale di Bentivoglio

Azienda Unità Sanitaria Locale

Anestesia e Rianimazione - Ospedale Bellaria

Anestesia e Rianimazione - Policlinico Universitario S.Orsola - Malpighi

Anestesia e Terapia intensiva dei trapianti addominali e chirurgia epatobiliare - Policlinico Universitario S.Orsola - Malpighi

Anestesia e Terapia Intensiva Polivalente - Policlinico Universitario S.Orsola - Malpighi

Ospedale SS. Trinità - Anestesia e Rianimazione

Anestesia e Rianimazione - Ospedale M. Bufalini

Anestesia e Rianimazione - Ospedale degli Infermi

Anestesia e Rianimazione Universitaria - Arcispedale Sant'Anna Ferrara

Anestesia e Rianimazione - Ospedale Morgagni - Pierantoni

Anestesia e Rianimazione - Ospedale di Imola S.Maria della Scaletta

Ospedale Santo Stefano - Anestesia e Rianimazione

Anestesia e Rianimazione - Ospedale S. Maria delle Croci

Anestesia e Rianimazione - Arcispedale Santa Maria Nuova

Anestesia e Rianimazione - Ospedale di Riccione

Anestesia e Rianimazione - Ospedale Infermi

Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome

Ventilator free days (VFDs) will be calculated in a time frame of 28 days, the beginning of observation will coincide with the day of intubation and observation will end after successful disconnection from mechanical ventilation.
For intubated patients, post extubation non invasive ventilation (NIV) will not be accounted as a ventilation period, in case of interval reintubation within 28 days, VFDs will be counted from the last successful extubation.
For tracheostomized patients, ventilator free days will be counted after successful disconnection from mechanical ventilation and interval reconnections will be considered in the ventilation interval as for intubated patients.

15D instrument (http://www.15d-instrument.net/15d/) will be administered via telephonic interview
Areas assessed: MOBILITY, VISION, HEARING, BREATHING, SLEEPING, EATING, SPEECH, EXCRETION, USUAL ACTIVITIES, MENTAL FUNCTION, DISCOMFORT AND SYMPTOMS, DEPRESSION, DISTRESS, VITALITY, SEXUAL ACTIVITY

First available CT, last CT before ICU admission and intubation, last ICU follow-up CT. First available chest X ray, last chest X ray before ICU admission and intubation, last ICU- follow up chest X ray and 30 days follow-up CT (if available) will be evaluated, if available.
Structured description
CT scan
Date: yyyy/mm/dd Parenchymal alterations: ground glass, crazy paving, parenchymal consolidation Extension: monolateral, bilateral Number of lobes involved: (1-5) Percentage of parenchymal involvement: 0-100% Distribution: subpleural, random, diffuse
X-ray scan
Date: yyyy/mm/dd Main aspects: normal, focal lesions, monolateral multifocal lesions (right/left), diffuse multifocal lesions Lesion aspects: interstitial, interstitial/alveolar, alveolar, consolidations Pleural effusion presence and entity
Pulmonary involvement score:
0 = no involvement
=< 25%
= 25-50% 3= 50-75%
4 => 75% Total score (0-6): score of the right lung + score of the left lung

Azienda Usl di Bologna

Lorenzo Gamberini

Patients who developed severe COVID-19 disease (including fatal events)

Infected patients who did not develop severe COVID-19 respiratory disease (including individuals who recovered from the infection)

IRCCS Neuromed, Department of Epidemiology and Prevention

ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19

Severity pneumonia or acute respiratory distress syndrome by COVID-19

Augusto Di Castelnuovo

MSc, PhD

Neuromed IRCCS

Delayed addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART

Immediate addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART

HIV Infection

Hydroxychloroquine 400mg once daily orally

Hydroxychloroquine

St Stephen's Centre

Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)

The Immunological Impact of Adding Hydroxychloroquine in Patients With Discordant CD4+ Cell Responses to Suppressive HAART: A Phase I Pilot Study.

To measure the change in CD4 from baseline after 12 weeks of hydroxychloroquine therapy

chloroquine/infarction

Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome

ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19

Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)

Baz done ki pi konplè remèd fèy medsin te apiye nan syans